Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis
Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Tyagi, Sanjay Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna · 2026
Read Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis by Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Tyagi, Sanjay Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0341988.txt.
Description
Zeeshan Sidiq and seven colleagues compare this 2026 PLOS One head-to-head evaluation of two rapid molecular tests for tuberculosis at a New Delhi center. Both tests are endorsed by the World Health Organization, but clinics also care about reliability, failed runs, and cost. More than six hundred people with suspected lung tuberculosis gave paired samples for the Truenat and Xpert Ultra systems, with culture as the reference.
Both tests were highly accurate. Xpert Ultra caught slightly more true cases and produced fewer failed results, while Truenat was cheaper and easier to run in small, decentralized settings, though repeat testing was needed more often. For drug resistance detection, both were perfectly specific but missed some resistant cases. The authors recommend a tiered approach that plays to each platform's strengths.
Catalog record
| CREATOR | Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Tyagi, Sanjay Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27343 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |